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The treatment of infectious diseases still remains an important
and challenging problem because of a combination factors
including emerging infectious diseases and increasing number
of multi-drug resistant microbial pathogens with particular rel-
evance for Gram-positive bacteria Tenover and McDonald,
2005; Pfeltz and Wilkinson, 2004; Roberts, 2004; Dessen91 8312471399; fax: +91
oo.co.in (S.G. Alegaon).
y. Production and hosting by
Saud University.
lsevieret al., 2001; Muroi et al., 2004). In spite of the large number
of antibiotics and chemotherapeutics available for medical
use, the emergence of old and new antibiotic resistant bacterial
strains in the last decades constitutes a substantial need for the
new class of antibacterial agents (Chopra et al., 2008).
The varied biological activities of rhodanines (2-thioxo-
thiazolidin-4-one) and their analogues have been known from
the beginning of the 20th century. Rhodanines and 2,4-thiazo-
lidinedione have become a pharmacologically important class
of heterocyclic compounds since the introduction of various
glitazones and epalrestat in to clinical use for the treatment
of type II diabetes and diabetic complications, respectively
(Terashima et al., 1984; Yoshioka et al., 1998). Chemical mod-
iﬁcation of these heterocycles has constantly resulted in com-
pounds with broad spectrum of pharmacological activities.
2,4-Thiazolidinedione derivatives constitute an important class
of heterocyclic compounds for which diverse biological prop-
erties such as antibacterial and antifungal (Ayhan-Kilcigil
and Altanlar, 2000; Heerding et al., 2003; Tuncbilek and
Altanlar, 2006; Bozdag-Dundar et al., 2007), antidiabetic
(Cantello et al., 1994), cardiotonic (Andreani et al., 1993),
466 K.R. Alagawadi, S.G. Alegaonanti-oedematus and analgesic (De-Lima et al., 1994), cycloox-
ygenase and lipoxygenase inhibitory (Boschelli et al., 1992)
activities have been documented along past decades. On other
hand a large number of imidazo[2,1-b][1,3,4]-thiadiazoles have
been reported to possess various pharmacological properties
such as anticancer (Terzioglu and Gursoy, 2003), antitubercu-
lar (Kolavi et al., 2006), antibacterial (Gadad et al., 2000),
antifungal (Andotra et al., 1997), anticonvulsant, analgesic
(Khazi et al., 1996) and antisecretory (Andreani et al., 2000).
In view of the facts mentioned above and as part of our initial
efforts to discover potentially active new agents, we report herein
the synthesis of 5-substituted-2,4-Thiazolidinedione derivatives
and evaluation of their antibacterial and antifungal activities.
2. Materials and methods
2.1. Materials and reagents
Unless otherwise noted, materials were obtained from com-
mercial suppliers and used without further puriﬁcation. Melt-
ing point was determined by electro thermal melting point
apparatus and is uncorrected. All reactions were monitored
by thin-layer chromatography (TLC) on 0.25 mm silica gel
(60GF-254) plates and visualized with UV light. Column chro-
matography was performed on silica gel (200–300 mesh). Infra
red (IR) spectra were recorded on using KBr disk on a Nicolet
MX-1 FTIR spectrophotometer, 1H NMR spectra were re-
corded AMX-400 and Bruker-400 liquid-state NMR spec-
trometer using tetramethylsilane (TMS) as internal standard
(chemical shift in d ppm). Mass spectra were recorded on a
JEOL MS-DX-303 spectrometer. Elemental analysis was car-
ried out using a Perkin Elmer 2400-CHN Analyzer. Spectra
facilities and elemental analysis were carried out by Sophisti-
cated Analytical Instruments Facility (SAIF) division of In-
dian Institute of Science, Bangalore, India.
2.2. Synthesis
2.2.1. Synthesis of 2,4-thiazolidinedione (1)
Thiourea (0.48 mol) was added to a stirred solution of chloro-
acetic acid (0.5 mol) in concentrated hydrochloric acid (80 ml)
and the reaction mixture was heated under reﬂux for 15 h. On
cooling the product was precipitated, ﬁltered, dried and recrys-
tallized from water. Yield 78%; m.p; 123–124 C.
1H NMR (DMSO-d6) d in ppm: 12.00 (s, 1H, NH), 4.14 (s,
2H); 1H NMR (DMSO-d6) D2O Exchange experiment d in
ppm: 4.16 (s, 2H); MS: m/z 116.4 [M].
2.2.2. Synthesis of 2-amino-5-(3,4,5-trimethoxyphenyl)-1,3,4-
thiadiazole (2)
A mixture of equimolar quantities of 3,4,5-trimethoxy benzoic
acid (0.1 mol), thiosemicarbazide (0.1 mol) and phosphorus
oxychloride (30 ml) was reﬂuxed gently for half an hour. After
cooling, water was added (90 ml) and the mixture was reﬂuxed
for 4 h and ﬁltered. The solution was neutralized by saturated
solution of potassium hydroxide. The precipitate was ﬁltered
and recrystallized from ethanol. Yield 80%; m.p; 205–208 C.
IR (KBr) cm1; 3590.6 (NH2), 3117 (ArACH), 1620
(C‚N). 1H NMR (DMSO-d6) d in ppm: 8.85 (s, 2H,
ANH2), 6.95 (d, 2H, C2, C6), 3.80 (s, 6H, C3AOCH3,
C5AOCH3), 3.83 (s, 3H, C4AOCH3).2.2.3. General procedure: synthesis of 2-(3,4,5-
trimethoxyphenyl) 6-(4’substituted aryl)imidazo[2,1-b]-
[1,3,4]-thiadiazoles 3a–g
A mixture of equimolar quantities of 2-amino-5-(3,4,5-trime-
thoxyphenyl)-1,3,4-thiadiazole (0.01 mol) and an appropriate
a-bromoketones (0.01 mol) was reﬂuxed in dry ethanol
(300 ml) for 10 h. Excess of solvent was removed under re-
duced pressure the solid hydrobromide salts suspended in
water, and neutralized by aqueous sodium carbonate solution
to get free base. It was ﬁltered, washed with water, dried and
recrystallized from suitable solvent.2.2.3.1. 2-(3,4,5-trimethoxyphenyl)-6-phenylimidazo[2,1-b][1,3,4]-
thiadiazole (3a). Yield 70%; m.p; 205–208 C; IR (KBr)
cm1; 3095, 3033, 2943, 1576, 1490, 1339, 1130, 843; 1H
NMR (DMSO-d6) d in ppm: 8.75 (s, 1H, H-5 imidazole),
7.40 (m, 5H, ArAH), 7.41 (d, 2H, ArAH), 3.89 (s, 6H,
2OCH3), 3.70 (s, 3H, OCH3).2.2.3.2. 2-(3,4,5-trimethoxyphenyl)-6-(4-methylphenyl)-imidazo
[2,1-b][1,3,4]thiadiazole (3b). Yield 71 %; m.p; 136–137 C;
IR (KBr) cm1; 3090, 3025, 2947, 1586, 1489, 1329, 1130, 839;
1H NMR (DMSO-d6) d in ppm: 8.64 (s, 1H, H-5 imidazole),
7.77 (d, 2H, ArAH), 7.22 (d, 2H, ArAH), 7.14 (d, 2H, ArAH),
3.89 (s, 6H, 2OCH3), 3.87 (s, 3H, OCH3), 3.29 (s, 3H, CH3).2.2.3.3. 2-(3,4,5-trimethoxyphenyl)-6-(4-methoxyphenyl)-imi-
dazo[2,1-b][1,3,4]thiadiazole (3c). Yield 70%; m.p; 205–
208 C; IR (KBr) cm1; 3085, 3043, 2973, 1596, 1481, 1343,
1150, 843; 1H NMR (DMSO-d6) d in ppm: 8.46 (s, 1H, H-5
imidazole), 7.62 (d, 2H, ArAH), 7.42 (d, 2H, ArAH), 7.14
(d, 2H, ArAH), 3.89 (s, 6H, 2OCH3), 3.87 (s, 3H, OCH3),
3.85 (s, 3H, OCH3).2.2.3.4. 2-(3,4,5-trimethoxyphenyl)-6-(4-nitrophenyl)-imidazo-
[2,1-b][1,3,4]thiadiazole (3d). Yield 70%; m.p; 205–208 C;
IR (KBr) cm1; 3060, 3021, 2959, 1587, 1494, 1346, 1128,
853; 1H NMR (DMSO-d6) in ppm: 8.85 (s, 1H, H-5 imidazole),
8.40 (d, 2H, ArAH), 8.16 (d, 2H, ArAH), 8.04 (d, 2H, ArAH),
3.89 (s, 6H, 2OCH3), 3.70 (s, 3H, OCH3).
2.2.3.5. 2-(3,4,5-trimethoxyphenyl)-6-(4-bromophenyl)-imidazo-
[2,1-b][1,3,4]thiadiazole (3e). Yield 70%; m.p; 188–190 C;
IR (KBr) cm1; 3095, 3043, 2944, 1586, 1490, 1329, 1130,
833; 1H NMR (DMSO-d6) d in ppm: 8.74 (s, 1H, H-5 imidaz-
ole), 8.30 (d, 2H, ArAH), 8.15 (d, 2H, ArAH), 8.07 (d, 2H,
ArAH), 3.90 (s, 6H, 2OCH3), 3.75 (s, 3H, OCH3).
2.2.3.6. 2-(3,4,5-trimethoxyphenyl)-6-(4-chlorophenyl)-imidazo-
[2,1-b][1,3,4]thiadiazole (3f). Yield 70%; m.p; 205–208 C;
IR (KBr) cm1; 3075, 3053, 2933, 1566, 1490, 1359, 1128,
833; 1H NMR (DMSO-d6) d in ppm: 8.76 (s, 1H, H-5 imidaz-
ole), 7.89 (d, 2H, ArAH), 7.49 (d, 2H, ArAH), 7.41 (d, 2H,
ArAH), 3.90 (s, 6H, 2OCH3), 3.75 (s, 3H, OCH3).
2.2.3.7. 2-(3,4,5-trimethoxyphenyl)-6-(6-(2,5-methoxyphenyl)-
imidazo[2,1-b][1,3,4]thiadiazole (3g). Yield 70%; m.p; 205–
208 C; IR (KBr) cm1; 3095, 3055, 2983, 1576, 1480, 1339,
1130, 843; 1H NMR (DMSO-d6) d in ppm: 8.56 (s, 1H, H-5
imidazole), 7.65 (m, 3H, ArAH), 7.24 (d, 2H, ArAH), 3.89
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(s, 3H, OCH3).
2.2.4. General procedure for the synthesis of 6-Aryl-2-(3,4,5-
trimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazole-5-
carbaldehyde 4a–g
Vilsmeier–Haak reagent was prepared by adding phosphoryl
chloride (3 ml), in dimethylformamide (20 ml), at 0 C with
stirring. Then appropriately substituted 2-alkyl/aryl-6-arylimi-
dazo[2,1-b][1,3,4]thiadiazole (3a–g 0.01 mol), was added to the
reagent and stirred at 0 C for 30 min. The mixture was further
stirred for 2 h at room temperature and at 60 C for additional
2 h. The reaction mixture was then poured in sodium carbon-
ate solution and stirred at 90 C for 2 h. After cooling, the mix-
ture was diluted with water, extracted with chloroform, and
collective extract was washed with water and dried over anhy-
drous sodium sulphate. The residue obtained after the removal
of chloroform was recrystallized from suitable solvent to get
the crystalline solid.
2.2.4.1. 6-phenyl-2-(3,4,5-trimethoxyphenyl)imidazo[2,1-b]-
[1,3,4]thiadiazole-5-carbaldehyde (4a). Yield 70%; Dark
brown crystals m.p; 180–182 C; IR (KBr) cm1; 3016, 2840,
2737, 1674, 1130, 732. 1H NMR (DMSO-d6) d in ppm: 10.09
(s, 1H, CHO), 7.60 (m, 5H, ArAH), 23 (d, 2H, ArAH), 3.91
(s, 6H, OCH3), 3.89 (s, 3H, OCH3)
2.2.4.2. 6-(4-methylphenyl)-2-(3,4,5-trimethoxyphenyl)imidazo-
[2,1-b][1,3,4]thiadiazole-5-carbaldehyde (4b). Yield 70%;
colourless crystals m.p; 145–148 C; IR (KBr) cm1; 3089,
2892, 2765, 1677, 1130, 798. 1H NMR (DMSO-d6) d in ppm:
10.05 (s, 1H, CHO), 7.88 (d, 2H, ArAH), 8.33 (d, 2H, ArAH),
7.22 (d, 2H, ArAH), 3.89 (s, 6H, OCH3), 3.76 (s, 3H, OCH3),
3.29 (s, 3H, CH3)
2.2.4.3. 6-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)imi-
dazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde (4c). Yield
70%; brownish product m.p; 155–157 C; IR (KBr) cm1;
3087, 2940, 2860, 2798, 1680, 1201, 1167, 823. 1H NMR
(DMSO-d6) d in ppm: 10.08 (s, 1H, CHO), 7.67 (d, 2H,
ArAH), 8.43 (d, 2H, ArAH), 7.24 (d, 2H, ArAH), 3.90 (s,
6H, OCH3), 3.74 (s, 3H, OCH3), 3.70 (s, 3H, OCH3)
2.2.4.4. 6-(4-nitrophenyl)-2-(3,4,5-trimethoxyphenyl)imidazo-
[2,1-b][1,3,4]thiadiazole-5-carbaldehyde (4d). Yield 70%;
brownish-yellow crystals m.p; 175–176 C; IR (KBr) cm1;
3056, 2976, 2835, 2787, 1674, 1204, 1354, 798. 1H NMR
(DMSO-d6) d in ppm: 9.55 (s, 1H, CHO), 7.86 (d, 2H, ArAH),
8.43 (d, 2H, ArAH), 7.21 (d, 2H, ArAH), 3.88 (s, 6H, OCH3),
3.87 (s, 3H, OCH3)
2.2.4.5. 6-(4-bromophenyl)-2-(3,4,5-trimethoxyphenyl)imidazo-
[2,1-b][1,3,4]thiadiazole-5-carbaldehyde (4e). Yield 70%;
light brown crystals m.p; 195–196 C; IR (KBr) cm1; 3050,
2945, 2854, 2789, 1680, 1167, 843, 788. 1H NMR (DMSO-
d6) d in ppm: 9.43 (s, 1H, CHO), 8.29 (d, 2H, ArAH), 8.15
(d, 2H, ArAH), 7.20 (d, 2H, ArAH), 3.87 (s, 6H, OCH3),
3.75 (s, 3H, OCH3)
2.2.4.6. 6-(4-chlorophenyl)-2-(3,4,5-trimethoxyphenyl)imidazo-
[2,1-b][1,3,4]thiadiazole-5-carbaldehyde (4f). Yield 70%;
dark brown crystals m.p; 176–178 C; IR (KBr) cm1; 3056,2894, 2793, 1673, 1203, 1156, 785. 1H NMR (DMSO-d6) d in
ppm: 10.09 (s, 1H, CHO), 8.06 (d, 2H, ArAH), 7.60 (d, 2H,
ArAH), 7.24 (d, 2H, ArAH), 3.91 (s, 6H, OCH3), 3.89 (s,
3H, OCH3)
2.2.4.7. 6-(2,5-dimethoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-
imidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde (4g). Yield
70%; brownish product m.p; 177–178 C; IR (KBr) cm1;
3076, 2914, 2773, 1669, 1234, 1136, 775.1H NMR (DMSO-
d6) d in ppm: 10.06 (s, 1H, CHO), 7.57 (m, 3H, ArAH), 7.24
(d, 2H, ArAH), 3.90 (s, 6H, OCH3), 3.74 (s, 3H, OCH3),
3.50 (s, 3H, OCH3), 3.47 (s, 3H, OCH3)
2.2.5. General procedure for the synthesis of 5-[(2-(3,4,5-
trimethoxyphenyl)-6-arylimidazo[2,1-b][1,3,4]thiadiazol-5-
yl)methylidene]-1,3-thiazolidine-2,4-dione 5a–g
A mixture of the 6-Aryl-2-(3,4,5-trimethoxyphenyl) imi-
dazo[2,1-b][1,3,4]thiadiazole-5-carbaldehyde 4a–g (0.001 mol),
2,4-thiazolidinedione (0.001 mol), piperidine (0.001 mol) and
acetic acid (0.001 mol) in toluene (50 ml) was heated under re-
ﬂux with azeotropic removal of water for 16 h. The mixture
was cooled to 5 C; ﬁltration gave crude 5-[(2-(3,4,5-trime-
thoxyphenyl)-6-arylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)meth-
ylidene]-1,3-thiazolidine-2,4-dione. The crude product was
recrystallized from appropriate solvents.
2.2.5.1. 5-[(2-(3,4,5-trimethoxyphenyl)-6-phenylimidazo[2,1-
b][1,3,4]thiadiazol-5-yl)methylidene]-1,3-thiazolidine-2,4-
dione (5a). Yield 77%; light yellow crystals; m.p; 198–200 C;
IR (KBr) cm1; 3395, 3077, 2976, 1730, 1700, 1610, 1330,
1176. 1H NMR (DMSO-d6) d in ppm: 12.50 (s, 1H, NH),
8.10 (d, 2H, ArAH), 7.77 (s, 1H, RACH‚C, TZD), 7.60
(m, 5H, ArAH), 3.91 (s, 6H, OCH3), 3.89 (s, 3H, OCH3). Anal.
Calcd for (C23H18N4O5S2) (%): C, 50.56; H, 3.67; N, 13.33.
Found; C, 50.76; H, 3.87; N, 11.37.
2.2.5.2. 5-{[2-(3,4,5-trimethoxyphenyl)-6-(4-methylphenyl)-
imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methylidene}-1,3-thiazoli-
dine-2,4-dione (5b). Yield 75%; light yellow crystals; m.p;
189–191 C; IR (KBr) cm1; 3380, 3060, 2965, 1725, 1696,
1615, 1330, 1166. 1H NMR (DMSO-d6) d in ppm: 12.40 (s,
1H, NH), 8.12 (d, 2H, ArAH), 7.74 (s, 1H, RACH‚C,TZD),
7.50 (m, 4H, ArAH), 3.91 (s, 6H, OCH3), 3.89 (s, 3H, OCH3),
3.49 (s, 3H, CH3). Anal. Calcd for (C24H20N4O5S2) (%): C,
56.68; H, 3.96; N, 11.02. Found; C, 50.70; H, 3.99; N, 11.35.
2.2.5.3. 5-{[2-(3,4,5-trimethoxyphenyl)-6-(4-methoxylphenyl)-
imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methylidene}-1,3-thiazoli-
dine-2,4-dione (5c). Yield 70%; yellow crystals; m.p; 205–
206 C; IR (KBr) cm1; 3340, 3080, 2956, 1735, 1698, 1620,
1320, 1156. 1H NMR (DMSO-d6) d in ppm: 12.35 (s, 1H,
NH), 8.14 (d, 2H, ArAH), 7.74 (s, 1H, RACH‚C,TZD),
7.60 (d, 2H, ArAH), 7.41 (d, 2H, ArAH), 3.90 (s, 6H,
OCH3), 3.89 (s, 3H, OCH3), 3.79 (s, 3H, OCH3). Anal. Calcd
for (C24H20N4O6S2) (%): C, 54.95; H, 3.84; N, 10.68. Found;
C, 54.99; H, 3.88; N, 10.86.
2.2.5.4. 5-{[2-(3,4,5-trimethoxyphenyl)-6-(4-nitrolphenyl)imi-
dazo[2,1-b][1,3,4]thiadiazol-5-yl]methylidene}-1,3-thiazoli-
dine-2,4-dione (5d). Yield 69%; yellow powder; m.p; 194–
195 C; IR (KBr) cm1; 3360, 3089, 2876, 1730, 1695, 1625,
1323, 1150. 1H NMR (DMSO-d6) d in ppm: 12.25 (s, 1H,
468 K.R. Alagawadi, S.G. AlegaonNH), 8.17 (d, 2H, ArAH), 7.77 (s, 1H, RACH‚C, TZD), 7.59
(d, 2H, ArAH), 7.49 (d, 2H, ArAH), 3.91 (s, 6H, OCH3), 3.89
(s, 3H, OCH3), Anal. Calcd for (C23H17N5O7S2) (%): C, 51.20;
H, 3.18; N, 12.98. Found; C, 51.29; H, 3.19; N, 12.99.
2.2.5.5. 5-{[2-(3,4,5-trimethoxyphenyl)-6-(4-bromophenyl)imi-
dazo[2,1-b][1,3,4]thiadiazol-5-yl]methylidene}-1,3-thiazoli-
dine-2,4-dione (5e). Yield 78%; yellowish orange powder; m.p;
210–211 C; IR (KBr) cm1; 3370, 3069, 2897, 1720, 1695,
1620, 1325, 1155. 1H NMR (DMSO-d6) d in ppm: 12.20 (s,
1H, NH), 8.27 (d, 2H, ArAH), 8.12 (d, 2H, ArAH), 7.67 (s,
1H, RACH‚C, TZD), 7.40 (d, 2H, ArAH), 3.99 (s, 6H,
OCH3), 3.87 (s, 3H, OCH3), Anal. Calcd for (C23H18
BrN4O5S2) (%): C, 48.17; H, 2.99; N, 9.77. Found; C, 48.29;
H, 3.03; N, 8.03.
2.2.5.6. 5-{[2-(3,4,5-trimethoxyphenyl)-6-(4-chlorophenyl)imi-
dazo[2,1-b][1,3,4]thiadiazol-5-yl]methylidene}-1,3-thiazoli-
dine-2,4-dione (5f). Yield 78%; light orange solid; m.p; 215–
216 C; IR (KBr) cm1; 3382, 3063, 2957, 1729, 1698, 1627,
1329, 1145. 1H NMR (DMSO-d6) d in ppm: 12.40 (s, 1H,
NH), 8.26 (d, 2H, ArAH), 8.15 (d, 2H, ArAH), 7.77 (s, 1H,
RACH‚C, TZD), 7.45 (d, 2H, ArAH), 3.97 (s, 6H, OCH3),
3.89 (s, 3H, OCH3), Anal. Calcd for (C23H18 ClN4O5S2)
(%): C, 52.22; H, 3.24; N, 10.59. Found; C, 52.24; H, 3.26;
N, 11.03.
2.2.5.7. 5-{[2-(3,4,5-trimethoxyphenyl)-6-(2,5-dimethoxylphe-
nyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methylidene}-1,3-thi-
azolidine-2,4-dione (5g). Yield 69%; light yellow solid; m.p;
213–215 C; IR (KBr) cm1; 3362, 3054, 2966, 1733, 1698,
1637, 1339, 1148. 1H NMR (DMSO-d6) d in ppm: 12.38 (s,
1H, NH), 8.26 (d, 2H, ArAH), 7.77 (s, 1H, RACH‚C,TZD),
7.45 (m, 3H, ArAH), 3.92 (s, 6H, OCH3), 3.81 (s, 3H, OCH3),
3.75 (s, 3H, OCH3), 3.73 (s, 3H, OCH3). Anal. Calcd for
(C25H22N4O7S2) (%): C, 54.14; H, 4.00; N, 10.10. Found; C,
54.16; H, 4.06; N, 10.13.
2.2.6. General procedure for the synthesis of N-
[(dimethylamino)methylidene]-5-[(2,4-dioxo-1,3-thiazolidin-5-
ylidene)methyl]-6-arylimidazo[2,1-b][1,3,4]thiadiazole-2-
sulfonamide 6a–g
A mixture of the N-(dimethylaminomethylidene)-5-formyl-6-
arylimidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide (0.001 mol),
2,4-thiazolidinedione (0.001 mol), piperidine (0.001 mol) and
acetic acid (0.001 mol) in toluene (50 ml) was heated under re-
ﬂux with azeotropic removal of water for 16 h. The mixture
was cooled to 5 C; ﬁltration gave crude N-[-(dimethyl-
amino)methylidene]-5-[-(2,4-dioxo-1,3-thiazolidin-5-ylidene)-
methyl]-6-arylimidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide.
The crude product was recrystallized from appropriate solvents.
2.2.6.1. Synthesis of N-[-(dimethylamino)methylidene]-5-[-
(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-6-phenylimi-
dazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide (6a). Condensa-
tion of 5-formyl-6-phenylimidazo[2,1-b][1,3,4]thiadiazole-2-
sulfonamide and 2,4-thiazolidinedione furnished bright yellow
crystals of N-[-(dimethylamino)methylidene]-5-[-(2,4-dioxo-
1,3-thiazolidin-5-ylidene)methyl]-6-phenylimidazo[2,1-b][1,3,4]-
thiadiazole-2-sulfonamide.
Yield 79%; light yellow solid; m.p; 236–238 C; IR (KBr)
cm1; 3407, 3090, 1735, 1699, 1610. 1H NMR (DMSO-d6) din ppm: 12.56 (s, 1H, NH), 8.40 (s, 1H, AN‚CHA), 7.77 (s,
1H, RACH‚C, TZD), 7.63–7.51 (m, 5H, ArAH), 3.24 (s,
3H of AN(CH3)2), 3.07 (s, 3H of AN(CH3)2). MS: m/z
463.53 [M+H]. Anal. Calcd for (C17H14N6O4S3) (%): C,
44.15; H, 3.06; N, 18.17. Found; C, 44.00; H, 3.00; N, 18.37.
2.2.6.2. Synthesis of N-[-(dimethylamino)methylidene]-5-[-
(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-6-(4-methyl-
phenyl)imidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide(6b).
Condensation of 5-formyl-6-(4-methylphenyl)imidazo[2,1-
b][1,3,4]thiadiazole-2-sulfonamide and 2,4-thiazolidinedione
furnished yellow crystals of N-[(dimethylamino)methylidene]-
5-[-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-6-(4-methyl-
phenyl)imidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide.
Yield 80%; light yellow solid; m.p; 260–261 C; IR (KBr)
cm1; 3433, 3080, 1730, 1707, 1612. 1H NMR (DMSO-d6) d
in ppm: 12.56 (s, 1H, NH), 8.38 (s, 1H, AN‚CHA), 8.25–
8.00 (m, 4H, ArAH), 7.77 (s, 1H, RACH‚C,TZD), 3.28 (s,
3H, CH3), 3.24 (s, 3H of AN(CH3)2), 3.03 (s, 3H of
AN(CH3)2), 2.30(s, 3H, ArACH3). MS: m/z 477.36 [M+H].
Anal. Calcd for (C18H16N6O4S3) (%): C, 45.37; H, 3.88; N,
17.63. Found; C, 45.30; H, 3.44; N, 18.66.
2.2.6.3. Synthesis of N-[-(dimethylamino)methylidene]-5-[-
(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-6-(4-methoxy-
phenyl)imidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide (6c).
Condensation of 5-formyl-6-(4-methoxyphenyl)imidazo[2,1-
b][1,3,4]thiadiazole-2-sulfonamide and 2,4-thiazolidinedione
yielded yellow solid N-[-(dimethylamino)methylidene]-5-[-
(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-6-(4-methoxy-
phenyl)imidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide.
Yield 81%; light yellow solid; m.p; 262–264 C; IR (KBr)
cm1; 3427, 3085, 2960, 1730, 1707, 1610. 1H NMR
(DMSO-d6) d in ppm: 12.56 (s, 1H, NH), 8.40 (s, 1H,
AN‚CHA), 7.77 (s, 1H, RACH‚C,TZD), 7.63 (d, 2H, C3,
C5, ArAH), 7.54 (d, 2H, C2, C6, ArAH), 3.32 (s, 3H,
OCH3), 3.24 (s, 3H of AN(CH3)2), 3.07 (s, 3H of AN(CH3)2).
MS: m/z 493.36 [M+H]. Anal. Calcd for (C18H16N6O5S3) (%):
C, 43.89; H, 3.27; N, 17.06. Found; C, 43.85; H, 3.25; N, 17.14.
2.2.6.4. Synthesis of N-[-(dimethylamino)methylidene]-5-[-
(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-6-(4-nitro-
phenyl)imidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide (6d).
Condensation of 5-formyl-6-(4-nitroyphenyl)imidazo[2,1-
b][1,3,4]thiadiazole-2-sulfonamide and 2,4-thiazolidinedione
yielded light yellow solid of N-[-(dimethylamino)methyli-
dene]-5-[-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-6-(4-
nitrophenyl)imidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide.
Yield 83%; light yellow solid; m.p; 258–260 C; IR (KBr)
cm1; 3443, 3080, 1730, 1699, 1615. 1H NMR (DMSO-d6) d
in ppm: 12.56 (s, 1H, NH), 8.40 (s, 1H, AN‚CHA), 8.29
(d, 2H, C2, C6–H phenyl), 8.14 (d, 2H, C3, C5 ArAH), 7.77
(s, 1H, RACH‚C, TZD), 3.28 (s, 3H, OH3), 3.32 (s, 3H of
AN (CH3)2), 3.02 (s, 3H of AN(CH3)2). MS: m/z 509 [M].
Anal. Calcd for (C17H15N7O6S3) (%): C, 40.07; H, 2.97; N,
19.24. Found; C, 44.10; H, 2.97; N, 19.28.
2.2.6.5. Synthesis of N-[-(dimethylamino)methylidene]-5-[-
(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-6-(4-bromophenyl)-
imidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide (6e). Conden-
sation of 6-(4-bromophenyl)-5-formylimidazo[2,1-b][1,3,4]thia-
diazole-2-sulfonamide and 2,4-thiazolidinedione furnished
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methylidene]-5-[-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-
imidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide.
Yield 82%; light yellow solid; m.p; 264–266 C; IR (KBr)
cm1; 3426, 3085, 1733, 1710, 1610. 1H NMR (DMSO-d6) d
in ppm: 12.59 (s, 1H, NH), 8.40 (s, 1H, AN‚CHA), 7.76 (s,
1H, RACH‚C,TZD), 7.75 (d, 2H, C2, C6, ArAH), 7.60 (d,
2H, C3, C5–H, Phenyl), 3.28 (s, 3H of AN(CH3)2), 3.06 (s,
3H of AN(CH3)2). MS: m/z 542.8 [M+H]. Anal. Calcd for
(C17H13BrN6O4S3) (%): C, 37.71; H, 2.42; N, 15.52. Found;
C, 37.69; H, 2.40; N, 15.50.
2.2.6.6. Synthesis of N-[-(dimethylamino)methylidene]-5-[-
(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-6-(4-chloro-
phenyl)imidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide (6f).
Condensation of 6-(4-chlorophenyl)-5-formylimidazo[2,1-
b][1,3,4]thiadiazole-2-sulfonamide and 2,4-thiazolidinedione
furnished yellow crystals of 6-(4-chlorophenyl)-N-[-(dimethyl-
amino)methylidene]-5-[-(2,4-dioxo-1,3-thiazolidin-5-yli-
dene)methyl]imidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide.
Yield 80%; light yellow solid; m.p; 272–274 C; IR (KBr)
cm1; 3434, 3085, 1730, 1698, 1610. 1H NMR (DMSO-d6) d
in ppm: 12.60 (s, 1H, NH), 8.46 (s, 1H, AN‚CHA), 7.75 (s,
1H, RACH‚C,TZD), 7.68 (d, 2H, C2, C, ArAH), 7.66 (d,
2H, C3, C5, ArAH), 3.28 (s, 3H of AN(CH3)2), 3.06 (s, 3H
of AN(CH3)2). MS: m/z 496.9 [M+H]. Anal. Calcd for
(C17H13ClN6O4S3) (%): C, 41.09; H, 2.64; N, 16.91. Found;
C, 41.00; H, 2.60; N, 16.94.
2.2.6.7. Synthesis of N-[-(dimethylamino)methylidene]-5-[-
(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-6-(2,5-methoxy-
phenyl)imidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide (6g).
Condensation of 5-formyl-6-(2,5-dimethoxyphenyl)imi-
dazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide and 2,4-thiazolid-
inedione yielded light yellow solid N-[-(dimethylamino)-
methylidene]-5-[-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-
6-(4-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazole-2-
sulfonamide.
Yield 78%; light yellow solid; m.p; 261–262 C; IR (KBr)
cm1; 3430, 3080, 2955, 1725, 1706, 1610. 1H NMR
(DMSO-d6) d in ppm: 12.60 (s, 1H, NH), 8.64 (s, 1H,
AN‚CHA), 7.67 (s, 1H, RACH‚C, TZD), 7.50 (m, 3H,
ArAH), 3.38 (s, 3H, OCH3), 3.32 (s, 3H, OCH3), 3.24 (s, 3H
of AN(CH3)2), 3.07 (s, 3H of AN(CH3)2). MS: m/z 553.46
[M+H]. Anal. Calcd for (C19H18N6O6S3) (%): C, 43.67; H,
3.47; N, 16.08. Found; C, 43.85; H, 3.48; N, 16.01.3. Antimicrobial activity
3.1. Microbiology
For the antibacterial and antifungal activity, the compounds
were dissolved in dimethylsulfoxide (DMSO). Further dilu-
tions of the compounds and standard drugs in the test medium
were prepared at the required quantities of 256, 128, 64, 32, 16,
8, 4, 2, 1 lg/ml concentrations with Mueller–Hinton broth and
Sabouraud dextrose broth. The minimum inhibitory concen-
trations (MIC) were determined using the twofold serial dilu-
tion technique (National Committee for Clinical Laboratory
Standards, 2000). A control test was also performed contain-
ing inoculated broth supplemented with only DMSO at thesame dilutions used in our experiments and found inactive in
the culture medium. All the compounds were tested for their
in vitro growth inhibitory activity against different bacteria
and fungi.
3.2. Antibacterial and antifungal activity
The cultures were obtained from Mueller–Hinton broth for all
the bacterial strains after 24 h of incubation at 37 ± 1 C.
Fungi were maintained in Sabouraud dextrose broth after
incubation for 24 h at 25 ± 1 C. Testing was carried out in
Mueller–Hinton broth and Sabouraud dextrose broth at pH
7.4 and the twofold serial dilution technique was applied.
The ﬁnal inoculum size was 105 CFU/ml for the antibacterial
assay and 104 CFU/ml for the antifungal assay. A set of tubes
containing only inoculated broth was used as controls. For the
antibacterial assay after incubation for 24 h at 37 ± 1 C and
after incubation for 48 h at 25 ± 1 C for antifungal assay, the
tube with no growth of microorganism was recorded to repre-
sent the MIC expressed in lg/ml. Every experiment in the anti-
bacterial and antifungal assay was replicated twice.
4. Results and discussion
4.1. Chemistry
The synthetic route of the compounds (5a–g and 6a–g) is out-
lined in Schemes 1 and 2, respectively. The 2,4-thiazolidinedi-
one 1 was prepared by cyclisation of equimolar quantities of
chloroacetic acid and thiourea by published procedures (And-
reani et al., 1993). 2-Amino-5-(3,4,5-trimethoxyphenyl)-1,3,4-
thiadiazole 2 was obtained by direct cyclisation of a 3,4,5-tri-
methoxy benzoic acid and thiosemicarbazide in the presence
of phosphorus oxychloride, the latter reﬂuxed with substituted
a-haloaryl ketones in dry ethanol yielded the imidazothiadiaz-
oles (3a–g) in good yield. It is well established that this reaction
proceeds via the intermediate iminothiadiazole antibacterial
(Gadad et al., 2000), which undergoes dehydrocyclisation to
form the desired fused heterocycle under reﬂux temperature
spontaneously. The electronic and steric factors at 5th position
of 2-Amino-5-substituted-1,3,4-thiadiazole are crucial in deter-
mining the course of its reaction with substituted a-haloaryl
ketones. The strongly electronegative groups impart less nucle-
ophilic character to the nitrogen at 4th position of the 1,3,4-
thiadiazole. Various a-haloaryl ketones were prepared by the
bromination of the corresponding ketones.
Vilsmeier–Haack reaction of imidazothiadiazoles (3a–g) in
dimethylformamide and phosphorus oxychloride provided 6-
Aryl-2-(3,4,5-trimethoxyphenyl) imidazo[2,1-b][1,3,4]thiadia-
zole–5-carbaldehyde derivatives (4a–g). The compounds (7a–
g) were prepared by the multi-step reaction protocol as previ-
ously reported antibacterial (Gadad et al., 2000),
Thus, obtained imidazo[2,1-b][1,3,4]thiadiazoles-5-carbal-
dehydes (4a–g) and (7a–g) were subjected to Knoevenagel con-
densation with 2,4-thiazolidinedione in the presence of
catalytic amount of piperidine and acetic acid to afford 5-
substituted-2,4-Thiazolidinediones (5a–g) and (6a–g),
respectively.
The formation of 2-Aminothiadiazole (2) by the reaction
between 3,4,5-trimethoxy benzoic acid and thiosemicarbazide
was conﬁrmed by IR spectra, which showed the presence of
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470 K.R. Alagawadi, S.G. Alegaonamine (ANH2) band and the absence of carbonyl stretching of
carboxylic acid. Structures of imidazothiadiazole derivatives (
3a–g) were established by the absence of amine (ANH2) band
in IR spectra and appearance of imidazole proton (H-5)
around d 8.6 in the 1H NMR spectra. IR spectra of aldehydes
(4a–g) displayed a sharp band for carbonyl stretching fre-
quency (vc‚o) around 1675 cm
1 and the signal for imidazoleproton (H-5) in 1H NMR spectrum was absent. A new signal
for aldehydic proton was observed around d 10.00 in the 1H
NMR spectra, thus substantiating the formation of imi-
dazo[2,1-b][1,3,4]thiadiazole-5-carbaldehydes. The absence of
aldehydic protons and presence of the methylidene proton
around d 7.7 in 1H NMR spectra of the product supported
the formation of the title compounds (5a–g) and (6a–g). The
Table 2 Inhibitory activity of compounds 5a–g and 6a–g expressed as minimum inhibitory concentration (MIC) in lg/mL.
Compounds Ar E.c P.a S.a E.f C.a C.n A.f A.n
5a C6H5 128 64 64 64 64 32 32 64
5b 4-CH3ÆC6H4 256 256 64 64 64 32 32 64
5c 4-OCH3ÆC6H4 256 256 64 64 64 64 64 32
5d 4-NO2ÆC6H4 256 256 64 64 16 64 08 64
5e 4-BrÆC6H4 256 256 32 32 4 8 4 4
5f 4-ClÆC6H4 128 64 32 32 4 8 32 32
5g 2,5-(OCH3)C6H3 128 128 64 128 32 64 64 64
6a C6H5 128 32 8 4 1 2 4 4
6b 4-CH3ÆC6H4 64 64 32 32 64 64 32 64
6c 4-OCH3ÆC6H4 64 64 32 32 64 32 64 32
6d 4-NO2ÆC6H4 64 64 32 64 32 64 64 32
6e 4-BrÆC6H4 64 64 8 8 4 8 4 4
6f 4-ClÆC6H4 64 64 8 4 32 64 32 4
6g 2,5-(OCH3)C6H3 128 128 64 64 32 8 32 64
Ampicillin 2 2 1 2 NT NT NT NT
Ketoconazole NT NT NT NT 2 1 2 1
NT, not tested; E.c, Escherichia coli; P.a, Pseudomonas aeruginosa; S.a, Staphylococcus aureus; E.f, Enterococcus faecalis; C.a, Candida albicans;
C.n, Cryptococcus neoformans; A.f, Aspergillus ﬂavus; A.n, Aspergillus niger.
Table 1 Physical Constants of the compounds 5a–g and 6a–g.
Compounds Ar Yield (%) m.p. (C) Molecular Formula
5a C6H5 77 198–200 C23H18N4O5S2
5b 4-CH3ÆC6H4 75 189–191 C24H20N4O5S2
5c 4-OCH3ÆC6H4 70 205–206 C24H20N4O6S2
5d 4-NO2ÆC6H4 69 194–195 C23H17N5O7S2
5e 4-BrÆC6H4 78 210–211 C23H18 BrN4O5S2
5f 4-ClÆC6H4 78 215–216 C23H18 ClN4O5S2
5g 2,5-(OCH3)C6H3 69 213–215 C25H22N4O7S2
6a C6H5 79 236–238 C17H14N6O4S3
6b 4-CH3ÆC6H4 80 260–261 C18H16N6O4S3
6c 4-OCH3ÆC6H4 81 262–264 C18H16N6O5S3
6d 4-NO2ÆC6H4 83 258–260 C17H15N7O6S3
6e 4-BrÆC6H4 82 264–266 C17H13BrN6O4S3
6f 4-ClÆC6H4 80 272–274 C17H13ClN6O4S3
6g 2,5-(OCH3)C6H3 78 261–262 C19H18N6O6S3
Synthesis, characterization and antimicrobial activity evaluation 471mass spectra and elemental analysis of these compounds fur-
ther conﬁrmed the assigned structures. The physical data and
the yield of the synthesized compounds are given in Table 1.4.2. Antimicrobial activity
The synthesized compounds were tested for their in vitro anti-
bacterial activity against the Gram-positive Staphylococcus
aureus (ATCC25923), Enterococcus faecalis (ATCC35550),
Gram-negative Escherichia coli (ATCC35218), Pseudomonas
aeruginosa (ATCC25619) bacteria and Candida albicans
(ATCC2091), Aspergillus ﬂavus (NCIM No. 524), Aspergillus
niger (ATCC6275), and Cryptococcus neoformans (Clinical iso-
late) fungi. The MIC values were determined by using the two-
fold serial dilution technique (National Committee for Clinical
Laboratory Standards, 2000) in Mueller–Hinton broth and
Sabouraud dextrose agar for the antibacterial and antifungal
assays, respectively. Ampicillin was used as the reference anti-
bacterial agents; ketoconazole was used as the reference anti-
fungal agents. All the biological results of the tested
compounds are given in Table 2. The combined data were re-ported that the synthesized compounds 5a–g and 6a–g showing
MIC values between 4–256 lg/ml and 4–64 lg/ml, respectively.
The investigation of antimicrobial screening revealed that
some of the tested compounds showed moderate to good bac-
terial and fungal inhibition. Particularly compounds 5e, 5f, 6a,
6b, 6c, 6e and 6f have shown good activity against S. aureus
and E. faecalis with MIC values between 4 and 32 lg/ml. All
compounds were active against tested fungal strains at 1–
64 lg/ml concentration. Some of the compounds 5e, 5f, 6a
and 6e showed good antifungal activity against C. albicans at
1–4 lg/ml and 5e, 6a and 6e against C. neoformans. A. ﬂavus.
A. niger at 2–8 lg/ml concentration. Compound 5f is active
against C. neoformans at 8 lg/ml and 6f against A. niger at
4 lg/ml concentration. From the results, it is evident that the
presence of 6-p-chlorophenyl and 6-p-bromophenyl derivatives
showed increased activity in series of 5-[(2-(3,4,5-trimethoxy-
phenyl)-6-arylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylidene]-
1,3-thiazolidine-2, 4-dione 5a–g in case N-[(dimethyl-
amino)methylidene]-5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)-
methyl]-6-arylimidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide
6a–g series 6-phenyl, 6-p-chlorophenyl and 6-p-bromophenyl
derivatives showed very good biological activity.
472 K.R. Alagawadi, S.G. Alegaon5. Conclusion
We have synthesized series of novel 5-substituted-2,4-Thiazo-
lidinedione derivatives. The results of antimicrobial screening
revealed the discovery of new compounds series of antibacte-
rial and antifungal agents. The mode of action of these com-
pounds was unknown. This observation may promote a
further development of this group of 2,4-Thiazolidinediones
may lead to compounds with better pharmacological proﬁle
than standard antibacterial and antifungal drugs.Acknowledgements
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